Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Fenaux P, Gobbi M, Kropf PL, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian H, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein J, Gercheva-Kyuchukova L, Demeter J, Griffiths E, Yee K, Döhner K, Hao Y, Keer H, Azab M, Döhner H. Fenaux P, et al. Among authors: thomas x. Blood Adv. 2023 Sep 12;7(17):5027-5037. doi: 10.1182/bloodadvances.2023010179. Blood Adv. 2023. PMID: 37276510 Free PMC article. Clinical Trial.
Timed sequential chemotherapy for advanced acute myeloid leukemia.
Archimbaud E, Leblond V, Fenaux P, Dombret H, Cordonnier C, Dreyfus F, Cony-Makhoul P, Tilly H, Troussard X, Auzanneau G, Thomas X, Ffrench M, Marie JP. Archimbaud E, et al. Among authors: thomas x. Hematol Cell Ther. 1996 Apr;38(2):161-7. doi: 10.1007/s00282-996-0161-2. Hematol Cell Ther. 1996. PMID: 8931997 Clinical Trial.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E. Thomas X, et al. Leukemia. 1999 Aug;13(8):1214-20. doi: 10.1038/sj.leu.2401474. Leukemia. 1999. PMID: 10450749 Clinical Trial.
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.
Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thomas X, Rigal-Huguet F, Lioure B, Auvrignon A, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Socié G, Dombret H. Nguyen S, et al. Among authors: thomas x. Blood. 2002 May 15;99(10):3517-23. doi: 10.1182/blood.v99.10.3517. Blood. 2002. PMID: 11986202 Free article.
Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy.
Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X, Tigaud I, Raffoux E, Rousselot P, Sigaux F, Degos L, Castaigne S, Fenaux P, Dombret H. Boissel N, et al. Among authors: thomas x. Leukemia. 2002 Sep;16(9):1699-704. doi: 10.1038/sj.leu.2402622. Leukemia. 2002. PMID: 12200684 Clinical Trial.
Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.
Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, Fenaux P, Bourhis JH, Fegueux N, Charrin C, Boucheix C, Lhéritier V, Espérou H, MacIntyre E, Vernant JP, Fière D; Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group). Dombret H, et al. Among authors: thomas x. Blood. 2002 Oct 1;100(7):2357-66. doi: 10.1182/blood-2002-03-0704. Blood. 2002. PMID: 12239143 Free article.
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H; ALFA Group. Preudhomme C, et al. Among authors: thomas x. Blood. 2002 Oct 15;100(8):2717-23. doi: 10.1182/blood-2002-03-0990. Blood. 2002. PMID: 12351377 Free article.
Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study.
Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, de Revel T, Simon M, Dupriez B, Renoux M, Janvier M, Micléa JM, Thomas X, Bastard C, Preudhomme C, Bauters F, Degos L, Dombret H. Castaigne S, et al. Among authors: thomas x. Blood. 2004 Oct 15;104(8):2467-74. doi: 10.1182/blood-2003-10-3561. Epub 2004 May 13. Blood. 2004. PMID: 15142880 Free article. Clinical Trial.
Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.
de Labarthe A, Pautas C, Thomas X, de Botton S, Bordessoule D, Tilly H, de Revel T, Bastard C, Preudhomme C, Michallet M, Fenaux P, Bastie JN, Socié G, Cordonnier C, Dombret H; Acute Leukemia French Association. de Labarthe A, et al. Among authors: thomas x. Bone Marrow Transplant. 2005 Apr;35(8):767-73. doi: 10.1038/sj.bmt.1704884. Bone Marrow Transplant. 2005. PMID: 15735660 Clinical Trial.
445 results